BB Healthcare Trust PLC Issue of Equity & Total Voting Rights (2011M)
September 17 2021 - 11:09AM
UK Regulatory
TIDMBBH
RNS Number : 2011M
BB Healthcare Trust PLC
17 September 2021
17 September 2021
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY,
TO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH
AFRICA, JAPAN OR ANY MEMBER STATE OF THE EEA (FOR THE AVOIDANCE
OF DOUBT, THIS DOES NOT INCLUDE THE UK) OR TO ANY NATIONAL,
RESIDENT OR CITIZEN OF AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH
AFRICA, JAPAN OR ANY MEMBER STATE OF THE EEA (FOR THE AVOIDANCE
OF DOUBT, THIS DOES NOT INCLUDE THE UK)
BB Healthcare Trust plc
Issue of Ordinary Shares
BB Healthcare Trust plc (the "Company") announces that it has
today issued 311,221 of its ordinary shares of one penny each
("Ordinary Shares") pursuant to its block listing facility.
The Ordinary Shares will be issued at a price of 197.00 pence
per Ordinary Share, a premium to the prevailing net asset value
("cum income") per Ordinary Share.
Following the issue of Ordinary Shares, the Company's issued
share capital will comprise (553,149,086) Ordinary Shares and
this is the total number of Ordinary Shares with voting rights
in the Company. This figure (553,149,086) may be used by shareholders
as the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change
to, their interest in the Company under the Financial Conduct
Authority's Disclosure Guidance and Transparency Rules.
The Company's LEI is: 213800HQ3J3H9YF2UI82
For further information please contact:
Bellevue Asset Management (UK) Ltd.
Mark Ghahramani
Telephone: +44 (0) 203 326 2981
J.P. Morgan Cazenove
James Bouverat (Sales)
Telephone: +44 (0) 207 134 2224
Alvarium Securities Limited
Mark Thompson +44 (0)20 7016 6711
Eddie Nissen +44 (0)20 7016 6713
Oliver Kenyon +44 (0)20 7195 1448
Disclaimer
This announcement does not constitute a prospectus relating
to the Company and does not constitute, or form part of, any
offer or invitation to sell or issue, or any solicitation of
any offer to purchase or subscribe for, any shares in the Company
in any jurisdiction nor shall it, or any part of it, or the
fact of its distribution, form the basis of, or be relied on
in connection with or act as any inducement to enter into, any
contract therefore.
J.P. Morgan Cazenove and Alvarium Securities Limited, which
are authorised and regulated by the Financial Conduct Authority,
are acting for the Company only in connection with the matters
described in this announcement and are not acting for or advising
any other person, or treating any other person as their client,
in relation thereto and will not be responsible for providing
the regulatory protection afforded to clients of Alvarium Securities
Limited and J.P. Morgan Cazenove or advice to any other person
in relation to the matters contained herein.
The shares of the Company have not been and will not be registered
under the US Securities Act of 1933, and may not be offered
or sold in the United States absent registration or an applicable
exemption from the registration requirements. Moreover, the
shares of the Company have not been, nor will they be, registered
under the applicable securities laws of Australia, Canada, the
Republic of South Africa, Japan or any member state of the EEA
(other than the United Kingdom). Further, the Company will not
be registered under the US Investment Company Act of 1940, as
amended. Subject to certain exceptions, the shares of the Company
may not be offered or sold in the United States, Australia,
Canada, the Republic of South Africa, Japan or any member state
of the EEA (other than the United Kingdom or to professional
investors in Ireland) or to, or for the account or benefit of,
any national, resident or citizen of the United States, Australia,
Canada, the Republic of South Africa, Japan or any member state
of the EEA (other than the United Kingdom or to professional
investors in Ireland). The share issuance programme, and the
distribution of this announcement, in other jurisdictions may
be restricted by law and the persons into whose possession this
announcement comes should inform themselves about, and observe,
any such restrictions.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEBUGDCLGBDGBR
(END) Dow Jones Newswires
September 17, 2021 11:09 ET (15:09 GMT)
Bellevue Healthcare (LSE:BBH)
Historical Stock Chart
From Apr 2024 to May 2024
Bellevue Healthcare (LSE:BBH)
Historical Stock Chart
From May 2023 to May 2024